Phase 2 N=18 Use of F-652 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=100 Omega 3 Fatty Acids in Patients With Chronic Renal Disease
Renal Insufficiency, Chronic
Primary: Number of Participants With a Urine Albumin Excretion Decrease of 20% or More — 19; 13 Participants — p=0.257
Phase 1 N=135 Injection of Local Anesthetic to Trocar Insertion Sites After Laparoscopy
Pain, Postoperative
Primary: Postoperative Pain Score Evaluated by Numerical Rating Scale (NRS) — 4.1; 3.4 units on a scale
Phase 3 N=129 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Bone Metastases in Men With Hormone-Refractory Prostate Cancer · Bone Metastases in Subjects With Advanced Breast Cancer
Primary: Number of Participants With Adverse Events — 98; 45; 28; 22 Participants
N/A N=40 Occupational Therapy in Complex Patients: a Pilot Study
Complex Patients in Rehabilitation Phase
Primary: Change From Baseline to Follow-up of the Performance Score at the Canadian Occupational Performance Measure — 7.28; 4.77 units on a scale
Phase 3 N=174 "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
Obstructive Sleep Apnea
Primary: Change in the Maintenance of Wakefulness Test (MWT) — -0.96; -12.11 minutes
Phase 3 N=69 Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Hypercholesterolaemia
Primary: Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm Period — 0.5 percentage of PTCs
Phase 1 N=15 First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
Advanced Solid Tumor
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs — 3; 3; 6; 3 Participants
N/A N=72 Improving Neuropathy and Mobility in People With Early Diabetes
Diabetes · Physical Activity
Primary: Six Minute Walk (6MW) Test — 156.644156; 61.257846 feet
N/A N=120 Early Literacy Promotion Intervention
Child Development
Primary: Change in Preschool Language Scale-5th Edition Score — -8.2; -9.0; -3.9; -2.0 score on a scale — p=0.85
Phase 4 N=222 The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
Hepatic Encephalopathy · Cirrhosis
Primary: Number of Participants Reporting a First Breakthrough HE Episode — 28; 15 Participants — p=0.0359
N/A N=23 4-week Mindfulness Program for Adults With Chronic Pain
Chronic Pain
Primary: Feasibility - Study Retention — 0.96 Proportion of participants
N/A N=108 Hospital Admissions in Children Aged 3 Months to 5 Years Presenting With Fever to the Emergency Department
Fever
Primary: Number of Participants With Admission to Hospital Due to Parental High Levels of Worry — 87 Participants
N/A N=6 Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan
Heart Failure
Primary: Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days — 6 Participants
N/A N=68 Improving Vitamin D Status in Home-bound Elders
Vitamin D Deficiency · Accidental Falls
Primary: Change in 25-hydroxyvitamin D Levels Over 5 Months — 21.7; 0 ng/mL